These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21538522)

  • 21. Homozygous THAP1 mutations as cause of early-onset generalized dystonia.
    Schneider SA; Ramirez A; Shafiee K; Kaiser FJ; Erogullari A; Brüggemann N; Winkler S; Bahman I; Osmanovic A; Shafa MA; Bhatia KP; Najmabadi H; Klein C; Lohmann K
    Mov Disord; 2011 Apr; 26(5):858-61. PubMed ID: 21425335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Results of using botulism toxin in the treatment of spasmodic dysphonia].
    Larrosa F; Idígora A; Aguilar F; Riera L; Martí MJ; Valls J
    Acta Otorrinolaringol Esp; 2002 Jan; 53(1):27-31. PubMed ID: 11998515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational screening of THAP1 in a German population with primary dystonia.
    Kaffe M; Gross N; Castrop F; Dresel C; Gieger C; Lichtner P; Haslinger B; Winkelmann J
    Parkinsonism Relat Disord; 2012 Jan; 18(1):104-6. PubMed ID: 21782490
    [No Abstract]   [Full Text] [Related]  

  • 24. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
    Hogikyan ND; Wodchis WP; Spak C; Kileny PR
    J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The point-touch technique for botulinum toxin injection in adductor spasmodic dysphonia: quality of life assessment.
    Morzaria S; Damrose EJ
    J Laryngol Otol; 2011 Jul; 125(7):714-8. PubMed ID: 21524329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia.
    Damrose JF; Goldman SN; Groessl EJ; Orloff LA
    J Voice; 2004 Sep; 18(3):415-22. PubMed ID: 15331116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrafamilial variability of the primary dystonia DYT6 phenotype caused by p.Cys5Trp mutation in THAP1 gene.
    Jurek M; Hoffman-Zacharska D; Koziorowski D; Mądry J; Friedman A; Bal J
    Neurol Neurochir Pol; 2014; 48(4):254-7. PubMed ID: 25168324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia.
    Adams SG; Hunt EJ; Irish JC; Charles DA; Lang AE; Durkin LC; Wong DL
    J Otolaryngol; 1995 Dec; 24(6):345-51. PubMed ID: 8699600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Applications of botulin].
    Lindberg L; Kanerva M; Pitkäranta A; Ansaranta M; Ylitalo L; Aaltonen LM; Pakarinen M; Salmenkylä S
    Duodecim; 2011; 127(22):2431-43. PubMed ID: 22238921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The dystonia gene DYT1 is repressed by the transcription factor THAP1 (DYT6).
    Kaiser FJ; Osmanoric A; Rakovic A; Erogullari A; Uflacker N; Braunholz D; Lohnau T; Orolicki S; Albrecht M; Gillessen-Kaesbach G; Klein C; Lohmann K
    Ann Neurol; 2010 Oct; 68(4):554-9. PubMed ID: 20976771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Spasmodic dysphonia. Investigation and therapeutic methods].
    Marion MH; Klap P; Perrin A; Elbaz E
    Rev Neurol (Paris); 1992; 148(3):180-3. PubMed ID: 1604131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenotype- and genotype-specific structural alterations in spasmodic dysphonia.
    Bianchi S; Battistella G; Huddleston H; Scharf R; Fleysher L; Rumbach AF; Frucht SJ; Blitzer A; Ozelius LJ; Simonyan K
    Mov Disord; 2017 Apr; 32(4):560-568. PubMed ID: 28186656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A method for the treatment of abductor spasmodic dysphonia with botulinum toxin injections: a preliminary report.
    Rontal M; Rontal E; Rolnick M; Merson R; Silverman B; Truong DD
    Laryngoscope; 1991 Aug; 101(8):911-4. PubMed ID: 1865744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia.
    Wong DL; Adams SG; Irish JC; Durkin LC; Hunt EJ; Charlton MP
    J Otolaryngol; 1995 Aug; 24(4):209-16. PubMed ID: 8551532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs.
    Watts CR; Truong DD; Nye C
    J Neural Transm (Vienna); 2008; 115(4):625-30. PubMed ID: 17564757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors and demographics in patients with spasmodic dysphonia.
    Schweinfurth JM; Billante M; Courey MS
    Laryngoscope; 2002 Feb; 112(2):220-3. PubMed ID: 11889373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. THAP1: role in focal dystonia?
    Ozelius LJ; Bressman SB
    Neurology; 2010 Jan; 74(3):192-3. PubMed ID: 20083795
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings.
    Zwirner P; Murry T; Swenson M; Woodson GE
    Laryngoscope; 1992 Apr; 102(4):400-6. PubMed ID: 1556889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia.
    Maloney AP; Morrison MD
    J Otolaryngol; 1994 Jun; 23(3):160-4. PubMed ID: 8064952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whispering dysphonia in an Australian family (DYT4): a clinical and genetic reappraisal.
    Wilcox RA; Winkler S; Lohmann K; Klein C
    Mov Disord; 2011 Nov; 26(13):2404-8. PubMed ID: 21956287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.